Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 520-528

  Mikkaichi, Tsuyoshi ^a   Yoshigae, Yasushi ^a   Masumoto, Hiroshi ^b   Imaoka, Tomoki ^a   Rozehnal, Veronika ^a   Fischer, Thomas ^a   Okudaira, Noriko ^a   Izumi, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; BUTYRIC ACID; CYCLOSPORIN A; DIGOXIN; EDOXABAN; ERYTHROMYCIN; ESTRONE SULFATE; KETOCONAZOLE; METFORMIN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PROBENECID; QUINIDINE; RIFAMPICIN; TRANSFERRIN; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BINDING; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; IC 50; IN VIVO STUDY; INTESTINAL SECRETION; KIDNEY TUBULE EXCRETION; LIVER CELL; MALE; MEMBRANE TRANSPORT; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINARY EXCRETION; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; FACTOR XA; HEK293 CELLS; HEPATOCYTES; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, KNOCKOUT; OOCYTES; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; P-GLYCOPROTEIN; PYRIDINES; SUBSTRATE SPECIFICITY; THIAZOLES; TISSUE DISTRIBUTION; XENOPUS LAEVIS;

EID: 84896111564     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054866     Document Type: Article

References (26)

1. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, and Mendell J (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 40:2250-2255.
2. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, and Choi JH, et al. (2009) Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497-504.
3. EMA (2012) Guideline on the Investigation of Drug Interactions, European Medicines Agency, London.
4. FDA (2012) Guidance for Industry, Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Center for Drug Evaluation and Research, Silver Spring, MD.
5. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181.
6. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, and Shibano T (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:1542-1549.
7. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
8. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
9. Laskin OL, de Miranda P, King DH, Page DA, Longstreth JA, Rocco L, and Lietman PS (1982) Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 21:804-807. (Pubitemid 12006532)
10. Li M, Anderson GD, and Wang J (2006) Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2:505-532. (Pubitemid 46127070)
11. Lixiana (2011) Package insert. Daiichi Sankyo Co., Ltd., Tokyo, Japan
12. Matsushima N, Lee F, Sato T, Weiss D, and Mendell J (2011) Absolute bioavailability of edoxaban in healthy subjects. AAPS J 13:T2362.
13. Mendell J, Noveck RJ, and ShiM(2012) Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol 60:335-341.
14. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M, and Shi M (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331-342.
15. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, and Kim RB (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298:F997-F1005.
16. Nutescu E, Chuatrisorn I, and Hellenbart E (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31:326-343.
17. Odlind B and Beermann B (1980) Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 27:784-790. (Pubitemid 10072965)
18. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, and Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743-753.
19. Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, and Mercuri M; Hokusai-VTE Investigators (2013) Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study - methodological implications for clinical trials. J Thromb Haemost 11:1287-1294.
20. Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, and Holt DW (1989) The digoxinamiodarone interaction. Cardiovasc Drugs Ther 3:25-28.
21. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, and Salazar D, et al. (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635-641.
22. Smit JW, Schinkel AH, Müller M, Weert B, and Meijer DK (1998) Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27:1056-1063. (Pubitemid 28160492)
23. Somogyi A, Stockley C, Keal J, Rolan P, and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551. (Pubitemid 17087957)
24. van Asperen J, van Tellingen O, and Beijnen JH (2000) The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28:264-267.
25. Yoshigae Y, Masumoto H, Okazaki O, and Izumi T (2010) Bioavailability, mass-balance, and metabolism of edoxaban after oral administration to rats and monkeys. AAPS J 12:W4378.
26. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168. (Pubitemid 32324448)